Vimseltinib
Orphan DrugFDA Approved (2025)
Description
An oral CSF1R inhibitor for tenosynovial giant cell tumor not amenable to surgery. FDA-approved February 2025.
Indications & Therapeutic Use
Tenosynovial giant cell tumor
Linked Diseases:
Global Availability (1 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| Standard Marketing Authorization | — | — | Approved |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Vimseltinib
| Generic Name | vimseltinib |
| Brands | 1 brand available |
| Active Ingredient | vimseltinib |
| Drug Class | Tenosynovial giant cell tumor |
| Manufacturer | Deciphera Pharmaceuticals |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Reg. Status | FDA Approved (2025) |
| Countries | 1 countries |
Authority Signals
Last Verified7/24/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations2 Validated Nodes